Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE trial of cangrelor bridging after thienopyridine discontinuation before CABG
NL-OMON34815Phase 2Active, not recruiting
- Sponsor
- The Medicines Company
- Start
- Dec 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS) and coronary arteriosclerosis comparing Cangrelor bridging with Placebo bridging (2 arms). Primary endpoint: Maintenance of platelet inhibition. Started Dec 2010; status: active, not recruiting.
02
Drugs
cangrelor
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON34815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34815.